UNSPSC 51361919: Proxibarbal or proxibarbital

This classification denotes a sedative and hypnotic with the molecular formula C10H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F97OMS297F, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-, (+-)- (9ci) but generally known as proxibarbal, which bears US NIH Compound Identifier 17336. European Medicines Agency schedules Proxibarbal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10147MIG.

UNSPSC 51361919 Proxibarbal or proxibarbital is a Commodity code that encompasses barbiturate pharmaceuticals; however, recent state and local procurement activity under this code shows minimal direct demand for the specific substance. The recent opportunities tagged to this code instead reflect broader pharmaceutical procurement patterns, including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical contracts. Where state and local jurisdictions do solicit under related pharmaceutical codes, they are procuring finished pharmaceutical products and systems for health, safety, and emergency response purposes—naloxone kits for opioid overdose reversal, drug deactivation equipment, generic medications for state health plans, and prescription fulfillment infrastructure. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating states).

Activity is concentrated in Florida and Texas, with multistate cooperative purchasing mechanisms drawing participation from the Upper Midwest and West. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (due July 26, 2023, with quarterly deliveries required), Texas HHS's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026, seeking vendor capabilities for therapeutic pharmacy initiatives), and Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with contract effectiveness July 1, 2026). The MMCAP contract explicitly requires vendors to supply through three authorized wholesalers and maintain compliance with cGMP and the Drug Supply Chain Security Act. Notably, none of these solicitations center on proxibarbital specifically; the code shows little targeted recent activity for barbiturate compounds at the state and local level.